Zydus and Gilead Sciences today announced that they signed a non-exclusive licensing agreement which will allow the generic manufacture of sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 90 developing countries, including India.

There are nearly 10 million patients suffering from hepatitis C in India. The problem is further compounded by the fact that patients remain undiagnosed till the late stage and can ill afford the treatment.

Shares of the company gained Rs 13.85, or 1.09%, to settle at Rs 1,285. The total volume of shares traded was 4,234 at the BSE (Monday).